{"id":"interleukin-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":{"setId":"f5853cc7-9c1f-7b24-345f-c258b8965894","title":"CONNECTISSUE (ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT, ASCORBIC ACID, METENKEFALIN, ERSOFERMIN, BOS TAURUS CARTILAGE, SUS SCROFA CARTILAGE, PORK COLLAGEN, BOS TAURUS RED BLOOD CELL, SUS SCROFA RED BLOOD CELL, INTERLEUKIN-3, INTERLEUKIN-3, BEEF LIVER, PORK LIVER, BEEF, PORK, BOS TAURUS TENDON, SUS SCROFA TENDON, CETERMIN) SPRAY [VIATREXX BIO INCORPORATED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-3 acts as a growth factor for bone marrow stem cells and early progenitor cells, enhancing the development of myeloid and lymphoid cell lines. It works by binding to the IL-3 receptor on target cells, triggering signaling cascades that increase cell proliferation, differentiation, and survival. This mechanism makes it useful for stimulating blood cell recovery in patients with compromised bone marrow function.","oneSentence":"Interleukin-3 is a cytokine that stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells, promoting the production of multiple blood cell lineages.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:30:09.865Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bone marrow failure and aplastic anemia"},{"name":"Myelodysplastic syndromes"},{"name":"Chemotherapy-induced myelosuppression"}]},"trialDetails":[{"nctId":"NCT06498973","phase":"PHASE1","title":"Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-01-28","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":43},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT05038592","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-04","conditions":"Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2","enrollment":64},{"nctId":"NCT05032183","phase":"PHASE1, PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-17","conditions":"Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT04317781","phase":"PHASE2","title":"Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-27","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":3},{"nctId":"NCT05720988","phase":"PHASE1","title":"Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-03","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT04744753","phase":"PHASE4","title":"AOA in Recurrent Fertilization Failure","status":"COMPLETED","sponsor":"MOHAMED BEHERY","startDate":"2017-07-15","conditions":"Infertility Primary","enrollment":150},{"nctId":"NCT00397579","phase":"PHASE1, PHASE2","title":"DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-05","conditions":"Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":11},{"nctId":"NCT01035697","phase":"","title":"Inflammatory Cytokines Associated With Perinatal Brain Injury","status":"COMPLETED","sponsor":"NICHD Neonatal Research Network","startDate":"1999-07","conditions":"Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age","enrollment":1067},{"nctId":"NCT01632852","phase":"PHASE1","title":"A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission","status":"COMPLETED","sponsor":"CSL Limited","startDate":"2012-07","conditions":"Leukemia, Myeloid, Acute","enrollment":30},{"nctId":"NCT00006225","phase":"PHASE1, PHASE2","title":"Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"1999-11","conditions":"Breast Cancer, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00005787","phase":"PHASE1","title":"Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Northwestern University","startDate":"1999-09","conditions":"Lymphoma, Neutropenia","enrollment":3},{"nctId":"NCT00001269","phase":"PHASE1","title":"Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1991-05","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":100},{"nctId":"NCT00002258","phase":"PHASE1","title":"A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia","status":"COMPLETED","sponsor":"Sandoz","startDate":"","conditions":"HIV Infections, Cytopenias","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5490,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Interleukin-3","genericName":"Interleukin-3","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interleukin-3 is a cytokine that stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells, promoting the production of multiple blood cell lineages. Used for Bone marrow failure syndromes, Myelodysplastic syndromes, Aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}